Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

In a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of personalized mRNA vaccines to treat the deadly disease. This research comes at a ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Currently More Than 400 Clinical Trials Studies Are Active In Saudi Arabia Says Kuick Research In New Research ReportDelhi, ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...

Collaboration reinforces Conduit's commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product t ...

Scientists report results from a promising new approach to treat the rare neurodegenerative disorder. Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before ...